Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
about
New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologistsIrritable bowel syndrome: new insights into symptom mechanisms and advances in treatmentDisorders of gastrointestinal hypomotilityAn Evidence-Based Look at Misconceptions in the Treatment of Patients with IBS-DRecent advances in pharmacological treatment of irritable bowel syndrome.A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotoninIrritable bowel syndrome--the main recommendations.An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium.Targeted therapies for diarrhea-predominant irritable bowel syndrome.Irritable bowel syndrome and ischemic colitis: evidence supporting the increased use of alosetron.Brain-Gut Interactions in IBSNew and Emerging Treatment Options for Irritable Bowel Syndrome.Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.Partial agonism of 5-HT3 receptors: a novel approach to the symptomatic treatment of IBS-DA 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program.Existing and emerging therapies for irritable bowel syndrome.The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.New treatments for IBS.Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature.Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome.The risks of risk aversion in drug regulation.Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation.Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome.Sumatriptan-associated ischemic colitis: case report and review of the literature and FAERS.Treatment of abdominal pain in irritable bowel syndrome.Current and emerging pharmacotherapeutic options for irritable bowel syndrome.Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System.Clozapine-induced acute gastrointestinal necrosis: a case report.Existing and emerging therapies for managing constipation and diarrhea.Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System.Retrospective analysis of disease association and outcome in histologically confirmed ischemic colitis.Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint.Pathological Conditions Associated with the Disturbance of the 5-HT System
P2860
Q26748617-EAA7B181-4FA8-4AFE-B7B2-ECC617108253Q26751193-9EA2FF77-9DE9-4675-B9C2-3DCE947DE30BQ28070278-AF66596C-1BCD-4B67-AD65-36D4C5572F73Q33667183-C56CA83A-B3D0-46AE-9538-BB9677E0B4EFQ33958853-EF100FA6-2B32-4A8F-8DB8-23D5104A873CQ34237231-3ADDFDE5-E7D7-43B4-9515-B907826D5436Q34790812-D4A05741-324D-4C8E-9315-74F53FADFB66Q35581343-18A4CBA2-358D-4919-BAEE-701103C55900Q35917169-8E172D9C-82C4-4B07-8A64-E791D69165D8Q36065945-2D5C8E6B-F8C4-4075-8D88-34685C4B4B5FQ36072690-6AAD7562-9A26-4BE3-8A77-D9DC36264085Q36076024-7936721E-2A27-48B0-BC8E-AAFEE01E5816Q36180769-6D7876F8-F501-42E5-BD1A-C8D1AA2238E1Q36297736-AF8E9358-A07A-495A-A8C3-CE58C3731E2CQ36543489-DA09A08F-96F9-437C-A06C-FAFF1BD3EE01Q37130608-A336AE27-F7C2-4A96-9118-29F6D9F505B1Q37857849-1090CAE5-4FD6-40EE-8E75-8AFEDF9323E0Q37887773-F7BBEBC2-436F-4B76-8489-5016DFA8EBEEQ38059436-0D2C585D-5D33-4FA9-A9CC-A37B34FF05A4Q38093766-EDB9930B-86D3-466C-AAF5-77BC075ECC08Q38102063-4D65EDE4-D01C-4C0A-AEE6-A8A9DF910157Q38162718-5DB855DF-C6DA-4607-8363-F3DB6CF85360Q38172854-181ABF77-2E61-4207-8863-B2E8352FAD36Q38175457-3B06FD7D-7B0B-4471-AC52-1F1028FCC954Q38180026-861E822D-4306-4AA1-ADE8-23DB9FE08FCFQ38213185-EB56D206-B41A-4073-B11F-FD7268EA15B1Q38254747-C29E0B85-EFEC-407D-A65D-2B02C190EA87Q38630721-4A83A1C0-A60A-4463-AB07-36279E8151E6Q38856699-1CDDBA61-33F7-43CA-9921-A282CA8E864AQ40803423-0AA42102-6E04-4FFA-8CD1-C5A00413D819Q42362955-B13ABC7E-3ABB-46B3-9F4B-A85186A7D45AQ49677641-5CAF5B0F-0B66-475A-821C-455CA776C9C2Q51072387-1279BF65-D104-440E-AF1E-8DA95547CEDFQ51272849-68E08585-9B22-4047-B379-6012C52D9F64Q55030643-7BAD1E35-7E69-4994-B5F7-40F85108240EQ59201274-B36F04CA-65B9-4DE8-A821-0F57E683D59F
P2860
Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Ischemic colitis and complicat ...... ics, outcomes, and incidences.
@en
Ischemic colitis and complicat ...... ics, outcomes, and incidences.
@nl
type
label
Ischemic colitis and complicat ...... ics, outcomes, and incidences.
@en
Ischemic colitis and complicat ...... ics, outcomes, and incidences.
@nl
prefLabel
Ischemic colitis and complicat ...... ics, outcomes, and incidences.
@en
Ischemic colitis and complicat ...... ics, outcomes, and incidences.
@nl
P2093
P2860
P356
P1476
Ischemic colitis and complicat ...... ics, outcomes, and incidences.
@en
P2093
Kenneth Tong
Vanessa Ameen
P2860
P304
P356
10.1038/AJG.2010.25
P407
P577
2010-03-02T00:00:00Z